99 related articles for article (PubMed ID: 8141112)
41. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial.
Hainsworth JD; Jones SE; Mennel RG; Blum JL; Greco FA
J Clin Oncol; 1996 May; 14(5):1611-6. PubMed ID: 8622079
[TBL] [Abstract][Full Text] [Related]
42. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
[TBL] [Abstract][Full Text] [Related]
43. Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies.
Valone FH; Gandara DR; Luce JA; Wall S; Perez EA; Braham N; George M; Letvak L
Cancer Chemother Pharmacol; 1993; 32(3):215-20. PubMed ID: 8500227
[TBL] [Abstract][Full Text] [Related]
44. A phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer.
Bhalla K; Birkhofer M; Bhalla M; Lutzky J; Hindenburg A; Cole J; Ince C
Am J Clin Oncol; 1991 Dec; 14(6):509-13. PubMed ID: 1957839
[TBL] [Abstract][Full Text] [Related]
45. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
46. 5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma.
Seitz JF; Perrier H; Giovannini M; Capodano G; Bernardini D; Bardou VJ
J Chemother; 1998 Jun; 10(3):258-65. PubMed ID: 9669654
[TBL] [Abstract][Full Text] [Related]
47. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
[TBL] [Abstract][Full Text] [Related]
48. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Alonso MC; Tabernero JM; Ojeda B; Llanos M; Solà C; Climent MA; Seguí MA; López JJ
Breast Cancer Res Treat; 1995 Apr; 34(1):15-24. PubMed ID: 7749156
[TBL] [Abstract][Full Text] [Related]
49. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
[TBL] [Abstract][Full Text] [Related]
50. A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.
Bailey H; Wilding G; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Grem JL; Spriggs DR
Cancer Chemother Pharmacol; 1992; 30(4):297-302. PubMed ID: 1643698
[TBL] [Abstract][Full Text] [Related]
51. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
[TBL] [Abstract][Full Text] [Related]
52. Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer.
Jones DV; Winn RJ; Brown BW; Levy LB; Pugh RP; Wade JL; Gross HM; Pendergrass KB; Levin B; Abbruzzese JL
Cancer; 1995 Nov; 76(10):1709-14. PubMed ID: 8625038
[TBL] [Abstract][Full Text] [Related]
53. Treatment of advanced breast cancer with 5-fluorouracil and high-dose folinic acid: preliminary results.
Marini G; Marpicati P; Zaniboni A; Cervi GC; Gorni F; Simoncini E
Chemioterapia; 1985 Apr; 4(2):135-8. PubMed ID: 3874000
[TBL] [Abstract][Full Text] [Related]
54. Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.
Sobrero AF; Aschele C; Guglielmi AP; Mori AM; Tixi LM; Bolli EA; Rosso R; Mammoliti S; Rollandi GA; Bertoglio S
Clin Cancer Res; 1995 Sep; 1(9):955-60. PubMed ID: 9816066
[TBL] [Abstract][Full Text] [Related]
55. High dose folinic acid and 5-fluorouracil bolus and continuous infusion for patients with advanced colorectal cancer.
Bécouarn YH; Brunet RC; Rouhier ML; Bussières EJ; Avril AR; Richaud PM; Dilhuydy JM
Cancer; 1995 Oct; 76(7):1126-31. PubMed ID: 8630887
[TBL] [Abstract][Full Text] [Related]
56. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
57. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
[TBL] [Abstract][Full Text] [Related]
58. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
Lévi FA; Zidani R; Vannetzel JM; Perpoint B; Focan C; Faggiuolo R; Chollet P; Garufi C; Itzhaki M; Dogliotti L
J Natl Cancer Inst; 1994 Nov; 86(21):1608-17. PubMed ID: 7932825
[TBL] [Abstract][Full Text] [Related]
59. Weekly 5-fluorouracil and high-dose folinic acid in combination with epidoxorubicin as first-line therapy in advanced breast cancer: a phase II study.
Stöger H; Bauernhofer T; Kasparek AK; Schmid M; Moser R; Ploner F; Derstvenscheg E; Kuss I; Wilders-Truschnig M; Steindorfer P
Cancer Chemother Pharmacol; 1994; 34(1):75-8. PubMed ID: 8174206
[TBL] [Abstract][Full Text] [Related]
60. Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen.
Streit M; Jaehde U; Stremetzne S; Ridwelski K; Kerz H; Strohbach F; Hohenberger P; Zwiebel FM; Hebart H; Böthig R; Kairies M; Zillig D; Schuchmann S; Warnecke S; Thiel E; Kreuser ED
Ann Oncol; 1997 Nov; 8(11):163-5. PubMed ID: 9426339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
